Valeo Pharma Inc.
VPHIF · OTC
10/31/2023 | 10/31/2022 | 10/31/2021 | 10/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 94.3% | 104.7% | 81.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 24.3% | 22.6% | 29.2% | 18.5% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -21.1% | -58% | -81% | -50.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -51.6% | -92.8% | -105% | -63.7% |
| EPS Diluted | -0.32 | -0.32 | -0.2 | -0.082 |
| % Growth | 0% | -60% | -143.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |